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P U B L I S H E D B Y E L S E V I E R I N C .LettersT Cell–Based Assay
of Pericardial Fluid
Mononuclear Cells for the
Diagnosis of Tuberculous
Pericardial EffusionDiagnosing tuberculous pericardial effusion (TPE)
remains a challenge despite continuing improve-
ments in microbiological and molecular techniques.
Recently, an enzyme-linked immunosorbent spot
(ELISPOT) assay was developed to count the
numbers of antimycobacterial effector T cells that
produce interferon (IFN)-gamma against Mycobacte-
rium tuberculosis-speciﬁc antigens encoded by genes
located in region of difference 1. However, the clinical
feasibility and usefulness of this method for diag-
nosing TPE have not been demonstrated.
We prospectively enrolled 35 consecutive patients
with a moderate to large amount of newly diagnosed
pericardial effusion who were hospitalized at Asan
Medical Center between July 1, 2008 and February 28,
2011. The hospital’s institutional review board
approved the study protocol, and patients’ informed
consents were obtained. All patients underwent peri-
cardiocentesis or a pericardial window operation.
Microbiological and pathological specimens were
processed for diagnosis of TPE. ELISPOT assays
(T-SPOT.TB, Oxford Immunotec, Abingdon, United
Kingdom) with M. tuberculosis–speciﬁc antigens
(ESAT-6 and CFP-10) were performed as previously
described (1). Mononuclear cells from the peripheral
blood and pericardial ﬂuid samples were used. A
negative control (NC) is a duplicate well containing no
antigen, and a positive control is a well containing
phytohemagglutinin. The resulting spots were coun-
ted using an automated microscope (ELiSpot 04 HR,
Autoimmune Diagnostika GmbH, Strassberg, Ger-
many). When an extremely high number of sensitized
T lymphocytes was counted as 1 by automatic spot
counting, the number was corrected to 2000. The
differences between the numbers of spots in the spe-
ciﬁc antigen-containing wells and NC wells were used
as continuous diagnostic variables to obviate the ef-
fect of background debris in the pericardial effusion.Adenosine deaminase (ADA) activity in pericardial
effusion was also measured. Decisions regarding
antituberculosis therapy were made by the attending
physicians on the basis of the laboratory ﬁndings and
clinical features of each patient, except for ELISPOT
assays results. The study investigators, without
knowledge the ELISPOT assay results, categorized
patients into 2 groups, TPE and non-TPE (NTPE),
using previously reported diagnostic criteria (2).
Of 35 patients, 12 and 23 patients were diagnosed
with TPE and NTPE, respectively. In the NTPE group,
11 and 12 patients were diagnosed with malignant
and idiopathic pericardial effusions, respectively. The
receiver-operating characteristic (ROC) curve analysis
showed that the areas under the curves of ELISPOT
assays using peripheral blood were 0.737 for D(ESAT-
6 – NC) and 0.792 for D(CFP-10 – NC), whereas those of
ELISPOT assays using pericardial ﬂuid were 0.895 for
D(ESAT-6 – NC) and 0.895 for D(CFP-10 – NC). When
pericardial ﬂuid was used, the optimal cutoff values
for the diagnosis of TPE were 39 for D(ESAT-6 – NC)
and 92 for D(CFP-10 – NC). When these cutoff levels
were used, the sensitivity and speciﬁcity were 92%
and 87% by D(ESAT-6 – NC) and 75% and 100% by
D(CFP-10 – NC), respectively. The acid-fast bacilli
stain and cultures for M. tuberculosis were performed
on all 35 patients. The results of the acid-fast bacilli
stain on pericardial effusion were negative in all 35
patients, and cultures for M. tuberculosis were posi-
tive in 3 patients. Polymerase chain reaction for
M. tuberculosis was performed in 31 (89%) patients,
and only 1 patient showed a positive result. Of
the 15 (43%) patients who underwent pericardial
biopsy, granuloma was found in the pericardial
tissue of 1 patient. The ADA level in pericardial
ﬂuid was measured in 30 patients (86%). The area
under the ROC curve of ADA levels was 0.931. The
optimal cutoff value was 42 U/l, and the sensitivity
and speciﬁcity by this cutoff value were 92% and
89%, respectively. The area under the ROC curve
was 0.981 when a combination of ADA and ELISPOT
assay results of pericardial ﬂuid was used for
the diagnosis of TPE (Figure 1A). Compared with
ADA level, net reclassiﬁcation index of a combina-
tion of ADA and ELISPOT results was 0.4167
(95% conﬁdence interval: 0.1075 to 0.7259). When
positive results in $2 of 3 variables (ADA level, D
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FIGURE 1 Diagnosis of Tuberculous Pericardial Effusion by the ELISPOT Assay
(A) Receiver-operating characteristic curve analysis for the diagnosis of tuberculous pericardial effusion by adenosine deaminase (ADA) level
and results from the enzyme-linked immunosorbent spot (ELISPOT) assay using pericardial effusion. (B) An example of ELISPOT using pe-
ripheral blood and pericardial effusion in patients with deﬁnitive tuberculous pericardial effusion. Solid black plates were entirely packed with
numerous spots, suggestive of an extremely high density of sensitized lymphocytes. AUC ¼ area under the curve; CI ¼ conﬁdence interval;
NC ¼ negative control; PC ¼ positive control.
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1967[ESAT-6 – NC] and D[CFP-10 – NC] on pericardial
effusion), as judged using the cutoff values deter-
mined in this study, were used as a diagnostic
criterion for TPE, sensitivity, speciﬁcity, and posi-
tive and negative predictive values were 92%,
100%, 100%, and 95%, respectively. In 4 patients
classiﬁed as deﬁnitive TPE, deﬁned as detection of
acid-fast bacilli in a stained smear or culture of
pericardial ﬂuid or detection of tubercle bacilli or
caseating granuloma on histological examination of
the pericardium (3), extremely strong positive re-
actions in the M. tuberculosis–speciﬁc antigen-
containing wells and positive controls were found
when pericardial ﬂuidwas analyzed using the ELISPOT
assay (Figure 1B).
The detection rate of tubercle bacilli on direct
smear examination of pericardial effusion is report-
edly low, ranging from 0% to 42%. The conventional
culture of tubercle bacilli from pericardial ﬂuid has a
detection rate of 53% (4). M. tuberculosis detection by
polymerase chain reaction has a low yield, ranging
from 50% to 81%. Therefore, it is not a suitable
diagnostic tool (5). Measuring ADA activity in peri-
cardial effusion is a useful method for diagnosing TPE
with a high sensitivity of 90%, but its diagnostic
power is limited by its relatively low speciﬁcity of
w74% (2). Our results indicate that the ELISPOT assay
using pericardial ﬂuid is a useful method for the
diagnosis of TPE and that it enhances speciﬁcitywhen used in combination with the assessment of
ADA activity in pericardial effusion.Sang Yong Om, MD
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Ventricular Arrhythmias
and Sleep-Disordered
Breathing in HF PatientsWe read with interest the study by Patton et al. (1)
on the unexpected absence of typical circadian
variation of ventricular arrhythmias observed in the
SCD-HeFT (Sudden Cardiac Death in Heart Failure
Trial). Sleep-disordered breathing (SDB), broadly
categorized into obstructive and central sleep ap-
nea, has been associated with increased cardiovas-
cular morbidity and mortality. Cardiac arrhythmias
are responsible for some of the higher cardiovas-
cular morbidity and mortality rates observed in
patients with SDB. The association between atrial
ﬁbrillation and SDB is well established, although
the association between SDB and life-threatening
ventricular arrhythmias also seems plausible.
Obstructive sleep apnea predicts sudden cardiac
death independently of other well-established risk
factors (2), and, unlike the general population, pa-
tients with SDB have a higher incidence of sudden
cardiac death during sleep (3). Studies consistently
report an SDB prevalence of $50% in the chronic
heart failure population. The prevalence of SDB
in patients with an implantable cardioverter-
deﬁbrillator (ICD) ranges between 57.8% and
66.3% (4,5). In a cohort of 472 ICD patients with
heart failure receiving cardiac resynchronization
therapy, a signiﬁcant risk enhancement of ventric-
ular arrhythmias and appropriate ICD therapies
owing to both central and obstructive sleep apnea
was found (5). Importantly, for heart failure pa-
tients with a primary inappropriate ICD therapies
(4). Patton et al. (1) observed an increase in the
onset of ventricular arrhythmias during sleep in
patients with an ICD and SDB. Data on SDB for pa-
tients enrolled in the SCD-HeFT were not reported.
Thus, it is our opinion that the observed deviation
in circadian variation of ventricular arrhythmias
reported by Patton et al. (1) may be inﬂuenced, atleast in part by the presence of SDB, a very pre-
valent condition among heart failure patients with
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61–74.REPLY: Circadian Variations of Ventricular
Arrhythmias and Sleep-Disordered Breathing
in HF PatientsWe appreciate the interest of Dr. Arias and colleagues
in our study of circadian and septadian patterns of
implantable cardioverter-deﬁbrillator therapy in the
SCD-HeFT (Sudden Cardiac Death in Heart Failure
Trial) population (1). In their Letter, they relevantly
highlight the importance of sleep-disordered brea-
thing as a trigger of ventricular arrhythmias and
implantable cardioverter-deﬁbrillator therapies. Both
central and obstructive sleep apnea exert strong
effects on the autonomic nervous system and are
known to be proarrhythmic (2).
We agree with Dr. Arias and colleagues that sleep-
disordered breathing is an important and increas-
ingly recognized trigger of arrhythmias (3). Unfortu-
nately, we do not have information on the presence
